We are seeking to expand PCR by making up to 3 additional awards of up to £500,000 each that can include salary, support, on costs and consumables.
Expression of interest: Deadline 7 January 2019.
Decisions will be communicated in February 2019.
Invited full applications: Deadline 30 April 2019.
Applications will be sent out to international peer review.
Grants will be made in early summer 2019. Programmes would normally run from 3 to 5 years.
The Award aims to:
Boost prostate cancer research
Build capacity in advanced prostate cancer research
We will accept applications from research scientists in any UK research institution.
Areas of research interest for this funding call
While we are interested in the areas of research below, we will consider any research avenues relevant to men suffering from advanced prostate cancer:
Early stage pilot research that can lead to future, larger research awards. Collaborative research will be encouraged. Interest from early career scientists is strongly encouraged.
Recognising that prostate cancer is not a single disease, research leading to new classifications or stratifications of prostate cancer that can improve targeting for existing therapies in advanced disease.
Translational research between scientists and clinicians that may translate into novel therapies into clinical treatment of advanced disease.
Expression of interests must be received by email to [email protected] by 5pm on Monday 7th January 2019. Successful applicants will be notified by mid-February 2019 with the details of how to prepare a full application.
To be kept up to date with future grant opportunities, send an email with "Grant Call Opt-in" in the subject line, your name and contact email to [email protected]
Bayer and Advanced Accelerator Applications (A Novartis Company) sponsor charity Prostate Cancer Research’s new collaborative project supported by IQVIA and backed by over 3,000 patients that aims to unleash the potential of health data